Clinical Trial Update: Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update investigating mechanisms of response to IMFINZI neoadjuvant therapy in non-small cell lung cancer using multiple-omics models (Phase 1/P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN